Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | DUT | P33316 | 3/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30007720 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL28067259 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL543110 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL22110849 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL23254274 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL8715 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL23254269 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL24695426 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| SCHEMBL22110735 | 1.00 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 | |
| Hydrochloric Acid SCHEMBL27275372 | 0.99 | SLC28A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129985-A2 | ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023183569-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | Molecular Assemblies, Inc. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023142803-A1 | ANTIVIRAL COMPOUND AND USE THEREOF | 北京恩泰伟医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023142803-A1 | ANTIVIRAL COMPOUND AND USE THEREOF | 北京恩泰伟医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023113038-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | リードファーマ株式会社 | 2023-06-22 | — | — | WO | disclosed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023004130-A1 | METHODS FOR PREPARING BISPHOSPHOCINS | Lakewood Amedex, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022133205-A1 | SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022035917-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-3888693-A1 | DRUG DELIVERY SYSTEM USING SOLUTION | Kyoto University (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-3533873-A1 | MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS | Translate Bio MA, Inc. (US) | 2019-09-04 | — | — | EP | disclosed |
| WO-2019071028-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES LLC (US) | 2019-04-11 | — | — | WO | disclosed |
| EP-2756080-B1 | MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS | TRANSLATE BIO MA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2018-07-26 | — | — | US | disclosed |
| EP-2958998-B1 | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | SIRNA THERAPEUTICS INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20120184457-A1 | Modulation of miRNA Activity | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-07-19 | — | — | US | disclosed |
| US-20120184457-A1 | Modulation of miRNA Activity | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-07-19 | — | — | US | disclosed |
| WO-2011015829-A1 | MODULATION OF MIRNA ACTIVITY | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207160-A1 | THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27 | HSPB1, HSP90B1, HSP90AB1 | SLC28A1 1280/4885SLC28A2 2488/4885SLC29A1 1512/4885 |
| US-20170216297-A1 | EFFICIENT INHIBITION OF HSP27 | HSPB1, HSP90AB2P, HSP90B1 | SLC28A1 182/4885SLC28A2 138/4885SLC29A1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.